Back to Oncology
Oncologyv2013Evidence-Based

IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma

Predicts survival in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapy and assists in treatment selection based on risk stratification

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
imdc score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Sum of risk factors: Time to therapy <1 year (1 point) + KPS <80% (1 point) + Hemoglobin below normal (1 point) + Calcium above normal (1 point) + Neutrophils above normal (1 point) + Platelets above normal (1 point)

Clinical Pearls & Practice Notes

  • Gold standard for risk stratification in metastatic renal cell carcinoma
  • Validated across multiple treatment settings including VEGF-targeted therapy and immunotherapy
  • Used in clinical trials to stratify patients and guide treatment selection
  • More than 50% of patients fall into intermediate risk category
  • Remains relevant in the era of modern immunotherapy combinations
  • Favorable risk patients may not benefit from ipilimumab + nivolumab vs sunitinib
  • Intermediate and poor risk patients derive survival benefit from combination immunotherapy
  • Normal laboratory ranges may vary by institution - use institutional normal limits
  • Also known as Heng criteria or IMDC criteria
  • Applicable to both clear cell and non-clear cell RCC

Evidence & Literature Citations

  1. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809
  2. Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013 Feb;14(2):141-8. doi: 10.1016/S1470-2045(12)70559-4
  3. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126

Score Interpretation Ranges

Tier 10 – 0 pts

0 risk factors

Tier 21 – 2 pts

1-2 risk factors

Tier 33 – 6 pts

3-6 risk factors

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.